Bevacizumab maintenance therapy — Competitive Intelligence Brief

Bevacizumab maintenance therapy (Bevacizumab maintenance therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiogenesis inhibitor. Area: Oncology.

phase 2 Angiogenesis inhibitor VEGF-A Oncology Small molecule

Target snapshot

Bevacizumab maintenance therapy (Bevacizumab maintenance therapy) — Sanofi. Inhibits vascular endothelial growth factor A (VEGF-A)

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bevacizumab maintenance therapy TARGET	Bevacizumab maintenance therapy	Sanofi	phase 2	Angiogenesis inhibitor	VEGF-A
Ziv aflibercept	Ziv aflibercept	Marashi Eye Clinic	marketed	VEGF inhibitor / Antiangiogenic agent	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Intravitreal Ranibizumabe	Intravitreal Ranibizumabe	University of Sao Paulo	marketed	VEGF-A inhibitor; monoclonal antibody fragment	VEGF-A (Vascular Endothelial Growth Factor A)
intra-vitreal injection of Ranibizumab	intra-vitreal injection of Ranibizumab	Ain Shams University	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Aflibercept (Eylea)	Aflibercept (Eylea)	Ahmad Zeeshan Jamil	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Aflibercept and ranibizumab	Aflibercept and ranibizumab	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (and VEGF-B for aflibercept)
Intravitreal Aflibercept Injection	Intravitreal Aflibercept Injection	Ophthalmic Consultants of Boston	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiogenesis inhibitor class)

1. Jiangsu Simcere Pharmaceutical Co., Ltd. · 3 drugs in this class
2. Eli Lilly and Company · 1 drug in this class
3. Guangzhou Institute of Respiratory Disease · 1 drug in this class
4. Hoffmann-La Roche · 1 drug in this class
5. Liaoning Cancer Hospital & Institute · 1 drug in this class
6. PPD Development, LP · 1 drug in this class
7. Peking University Cancer Hospital & Institute · 1 drug in this class
8. Sanofi · 1 drug in this class
9. ARCAGY/ GINECO GROUP · 1 drug in this class
10. Second Affiliated Hospital of Xi'an Jiaotong University · 1 drug in this class